- Home
- HNVR vs MRSN Comparison
HNVR vs MRSN Comparison
Compare HNVR & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HNVR | MRSN |
|---|---|---|
| Founded | 2008 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.6M | 138.8M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HNVR | MRSN |
|---|---|---|
| Price | $23.65 | $28.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $24.75 | ★ $30.38 |
| AVG Volume (30 Days) | 15.7K | ★ 72.4K |
| Earning Date | 01-28-2026 | 11-14-2025 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $68,038,000.00 | $33,180,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.67 | N/A |
| P/E Ratio | $15.29 | ★ N/A |
| Revenue Growth | ★ 10.44 | N/A |
| 52 Week Low | $17.47 | $5.21 |
| 52 Week High | $27.00 | $37.88 |
Technical Indicators
Market Signals| Indicator | HNVR | MRSN |
|---|---|---|
| Relative Strength Index (RSI) | 57.39 | 73.31 |
| Support Level | $23.22 | $28.11 |
| Resistance Level | $24.33 | $29.15 |
| Average True Range (ATR) | 0.35 | 0.46 |
| MACD | -0.10 | -0.56 |
| Stochastic Oscillator | 35.62 | 33.33 |
Price Performance
Historical ComparisonAbout HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.